AdultPediatricDosage Forms & Strengths injection, suspension 0.5mL prefilled syringe Conjugated to carrier protein (diphtheria CRM197 protein) Streptococcus pneumoniae Immunization Indicated for active immunization for prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae 0.5 mL IM once ACIP pneumococcal vaccine recommendations Pneumococcal vaccine-naïve or vaccination status unknown ≥65 years: 0.5 mL IM once; follow with dose of 23-valent PPSV ≥1 yr later 19-64 years with certain underlying medical conditions: 0.5 mL IM once (follow with PPSV23 >1 yr later); then, repeat regimen when aged ≥65 years PPSV23 previously received: May receive PCV15 ≥1 years after their last PPSV23 dose at discretion of physician PCV13 previously received: Public health benefits of providing PCV15 to adults who have received PCV13 only or both PCV13 and PPSV23 have not been evaluated; these adults should complete the previously recommended PPSV23 series For more information, see full ACIP recommendations at MMWR January 28, 2022 Dosage Modifications Renal or hepatic impairment Studies not conducted Dosing Considerations Vaccine serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F Contains all serotypes in Prevnar 13 plus 2 additional serotypes (22F and 33F) Specific medical conditions for aged 19-64 years Alcoholism Chronic heart, liver, or lung disease Cigarette smoking Diabetes mellitus Cochlear implant CSF leak Congenital or acquired asplenia Sickle cell disease or other hemoglobinopathies Chronic renal failure Congenital or acquired immunodeficiencies Generalized malignancy HIV infection Hodgkin disease, leukemia, lymphoma, multiple myeloma Iatrogenic immunosuppression Nephrotic syndrome Solid organ transplant Dosage Forms & Strengths injection, suspension 0.5mL prefilled syringe Conjugated to carrier protein (diphtheria CRM197 protein) Streptococcus pneumoniae Immunization Indicated for active immunization for prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae in children aged ≥6 weeks 4-dose series: 0.5 mL IM at 2, 4, 6, and 12-15 months of age First dose may be given as early as 6 weeks old 4-dose series initiated with lower valency pneumococcal conjugate vaccine can be completed with pneumococcal vaccine 15-valent Catch-up schedule for children who have never received a pneumococcal vaccine Aged at first dose 7-11 months: 3 doses; first 2 doses given at least 4 weeks apart; third dose given after one-year birthday, separated from the second dose by at least 2 months 12-23 months: 2 doses give at least 2 months apart 2-17 years: 1 dose Catch-up schedule for children previously vaccinated with a pneumococcal vaccine Administer single dose to children and adolescents aged 2-17 years who have received an incomplete series of another pneumococcal vaccine At least 2 months should elapse between receipt of the last dose of another pneumococcal conjugate vaccine and administration of pneumococcal vaccine 15-valent Dosage Modifications Renal or hepatic impairment Studies not conducted Dosing Considerations Vaccine serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F Contains all serotypes in Prevnar 13 plus 2 additional serotypes (22F and 33F) Interaction CheckerEnter a drug name and pneumococcal vaccine 15-valentNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (2)elivaldogene autotemcelelivaldogene autotemcel, pneumococcal vaccine 15-valent. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .teplizumabteplizumab decreases effects of pneumococcal vaccine 15-valent by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.Monitor Closely (5)delandistrogene moxeparvovecdelandistrogene moxeparvovec, pneumococcal vaccine 15-valent. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines.satralizumabsatralizumab decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. .tralokinumabtralokinumab will decrease the level or effect of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines.ublituximabublituximab decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells.voclosporinvoclosporin decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.Minor (0)delandistrogene moxeparvovecMonitor Closely (1)delandistrogene moxeparvovec, pneumococcal vaccine 15-valent. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines.elivaldogene autotemcelSerious - Use Alternative (1)elivaldogene autotemcel, pneumococcal vaccine 15-valent. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .satralizumabMonitor Closely (1)satralizumab decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. .teplizumabSerious - Use Alternative (1)teplizumab decreases effects of pneumococcal vaccine 15-valent by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.tralokinumabMonitor Closely (1)tralokinumab will decrease the level or effect of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines.ublituximabMonitor Closely (1)ublituximab decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells.voclosporinMonitor Closely (1)voclosporin decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment. >10% Adults All grades Pain (55.1-75.8%) Fatigue (18.1-34.3%) Myalgia (15.7-28.8%) Headache (13.4-26.5%) Swelling (14.2-21.7%) Erythema (7.9-15.1%) Arthralgia (5.5-12.7%) Pediatrics Moderate irritability (25-31.4%) Mild irritability (23.6-30.2%) Mild somnolence (13.9-24.2%) Mild pain (16.9-24.1%) Moderate somnolence (10-21.6%) Fever ≥38ºC (13.3-20.4%) Fever >38 to <39ºC (12.1-18.5%) Erythema ≤2.5 cm (11-15.4%) Moderate pain (8.8-14.7%) Decreased appetite, mild (7.5-12%) Induration ≤2.5 cm (7.5-11%) 1-10% Adults Fever 38ºC to <38.5ºC (0.6-1.6%) Grade 3 Fatigue (1%) Pain (1%) Pediatrics Swelling ≤2.5 cm (5.8-9.5%) Decreased appetite, moderate (5.7-7.9%) Erythema 2.5-7.6 cm (2.3-6.8%) Induration 2.5-7.6 cm (2.8-6.2%) Severe irritable (2.6-4.7%) Induration 2.5-7.6 cm (2.8-6.2%) Swelling 2.5-7.6 cm (3.2-5.5%) Fever ≥39 to <40ºC (0.7-2.4%) Severe somnolence (0.4-1.7%) Mild urticaria (0.8-1.7%) Moderate urticaria (0.2-1.5%) Severe pain (0.2-1.5%) <1% Adults Fever 38.5ºC to <39ºC (0.1-0.3%) Fever ≥39ºC (0.2%) Grade 3 Pain (0.8-0.9%) Erythema, >10 cm (0.5-0.8%) Headache (0.4-0.8%) Myalgia (0.3-0.8%) Fatigue (0.7%) Arthralgia (0.2-0.4%) Swelling, >10 cm (0.2-0.4%) Pediatrics Decreased appetite, severe (0.4-0.5%) Fever ≥40ºC (0.1-0.5%) Erythema >7.6 cm (0.2-0.3%) Severe urticaria (0.2%) Induration >7.6 cm (0.2%) Swelling >7.6 cm (0.2%) Contraindications Severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or to diphtheria toxoid Cautions Administer in facility with appropriate medical treatment to manage allergic reactions Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have reduced immune response Apnea following IM observed in some infants born prematurely; consider when to administer pneumococcal vaccine 15-vaccine premature infants based on infant’s medical status and potential benefits and possible risks Drug interaction overview Immunosuppressive therapies may reduce immune response to vaccine Pregnancy No adequate and well-controlled studies have been conducted in pregnant women; data are insufficient to inform vaccine-associated risks in pregnancy Animal studies Developmental toxicity studies in female rats administered a human dose have been conducted on 4 occasions (twice before mating, once during gestation, and once during lactation) These studies revealed no evidence of harm to the fetus Lactation Data are not available to assess vaccine impact on milk production, its presence in breast milk, or its effects on breastfed children Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on breastfed children from the drug or from underlying maternal condition; for preventive vaccines, the underlying condition is susceptibility to disease prevented by the vaccinePregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Protection against invasive disease conferred mainly by opsonophagocytic killing of S pneumoniae Vaccine induces opsonophagocytic activity against the serotypes contained in vaccine IM Preparation Hold syringe horizontally and shake vigorously immediately before administration to obtain an opalescent suspension Discard if it cannot be resuspended Inspect visually for particulate matter and discoloration; do not use if particulate matter or discoloration observed IM Administration For IM administration only Appropriate medical treatment to manage allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration Storage Refrigerate at 2-8ºC (36-46ºF) Do not freeze Protect from light Preservative-free suspension Tip cap and plunger stopper of prefilled syringe are not made with natural rubber latex No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print FormularyPatient DiscountsAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.Create Your List of PlansAdding plans allows you to:View the formulary and any restrictions for each plan.Manage and view all your plans together – even plans in different states.Compare formulary status to other drugs in the same class.Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions Tier Description 1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5 This drug is available at a higher level co-pay. Most commonly, these are